Chronic Obstructive Pulmonary Disease is a major global burden in terms of health economics, morbidity and mortality. COPD is characterized by marked neutrophilic inflammation which is progressive and poorly reversible. The underlying chronic inflammatory processes results in the complications of COPD viz. obstructive bronchiolitis, mucociliary dysfunction, airway hyper responsiveness and emphysema. Modeling COPD in animals for determining molecular and cellular targets is a complex task because of the associated differences in structural and functional aspects. Till date, corticosteroids and bronchodilators which are the mainstay for the therapy of the disease provide only symptomatic relief. Therefore, there is always a need of exploring novel targets, which can effectively abrogate the progression of the disease. In this context, therapeutic agents with a broad spectrum of anti-inflammatory profile may provide an effective strategy for the treatment of this devastating disease.